Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded 11.15% higher at $7.18 on Wall Street last session.
In accordance with the data, 7 analysts cover Recursion Pharmaceuticals Inc (NASDAQ:RXRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $9.00, we find $14.00. Given the previous closing price of $6.46, this indicates a potential upside of 116.72 percent. RXRX stock price is now 4.51% away from the 50-day moving average and -9.89% away from the 200-day moving average. The market capitalization of the company currently stands at $1.55B.
It has been rated a hold by 4 analysts and a buy by 3. Brokers who have rated the stock have averaged $15.57 as their price target over the next twelve months.
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX).
In other news, Gibson Christopher, Chief Executive Officer sold 37,177 shares of the company’s stock on Nov 01. The stock was sold for $193,306 at an average price of $5.20. Upon completion of the transaction, the Chief Executive Officer now directly owns 836,820 shares in the company, valued at $6.01 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, Chief Executive Officer Gibson Christopher sold 25,000 shares of the business’s stock. A total of $127,995 was realized by selling the stock at an average price of $5.12. Insiders disposed of 1,760,379 shares of company stock worth roughly $12.64 million over the past 1 year. A total of 34.50% of the company’s stock is owned by insiders.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened at $6.50 on Wednesday. During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 4.28, and a quick ratio of 4.28. The fifty day moving average price for RXRX is $6.87 and a two-hundred day moving average price translates $7.97 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.43, missing analysts’ expectations of -$0.38 by -0.05. This compares to -$0.35 EPS in the same period last year. The net profit margin was -617.74% and return on equity was -70.84% for RXRX. The company reported revenue of $10.53 million for the quarter, compared to $13.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -19.96 percent. For the current quarter, analysts expect RXRX to generate $20.53M in revenue.
Recursion Pharmaceuticals Inc(RXRX) Company Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.